How effective is tiotropium bromide and olodaterol inhalation spray?

Tiotropium bromide and olodaterol inhalation spray is an oral inhalation spray used to treat chronic obstructive pulmonary disease (COPD). It was approved by the U.S. Food and Drug Administration (FDA) in May 2015 as a long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (including chronic bronchitis and/or emphysema), but is not suitable for the treatment of asthma or acute exacerbations of chronic obstructive pulmonary disease.

Tiotropium bromide and olodaterol inhalation spray are administered using a propellant-free platform inhaler (called a Respimat), a common oral inhaler used for all respiratory treatments. Respimat delivers a unique spray that delivers medicine deep into the lungs. This medicine should be taken once a day in two divided inhalations. COPD is a group of chronic lung diseases, including chronic bronchitis and emphysema, that are caused by obstruction of airflow to the lungs. Common symptoms of COPD include difficulty breathing, excessive phlegm, and a chronic cough. The main causes of this disease are smoking, air pollution, dust and chemicals.

The original drug of tiotropium bromide and olodaterol inhalation spray has been launched in China. The specification (2.5mcg+2.5mcg)*60 sprays per box is about RMB 800. This drug may be sold in domestic hospitals or pharmacies. The original drug of tiotropium bromide and olodaterol inhalation spray has also been launched overseas. The Turkish version's specifications (2.5mcg+2.5mcg) * 60 sprays are priced at about 200 yuan per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of tiotropium bromide and olodaterol inhalation spray available on the market.